Fluorouracil in chemoprophylaxis of colorectal cancer. Results of a controlled clinical trial.
In a randomized prospective clinical trial in 128 patients undergoing radical surgical resection of primary colorectal cancer, 63 patients received intravenous fluorouracil (5-FU) in two courses, four and eight weeks after surgery; 65 controls received no chemotherapy. The duration of follow-up exceeded five years in all cases, and 28 patients have died in each group. Recurrent disease was present in 26 5-FU patients (41.2 percent) and in 22 controls (33.9 percent). There is no evidence that short-term 5-FU therapy was of significant value in the chemoprophylaxis of colorectal cancer.
D000368:Aged; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000401:mortality / Q000517:prevention & control*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000517:prevention & control*; D011446:Prospective Studies; D011897:Random Allocation; D012004:Rectal Neoplasms / Q000401:mortality / Q000517:prevention & control*
D005472:Fluorouracil